We found that the rs2280381-containing region acts as a distal and cell-type-specific enhancer to regulate IRF8 expression, suggesting that the rs2280381 enhancer has the potential to be a future SLE therapeutic target. The gene discussed is IRF8; the disease is systemic lupus erythematosus.